亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Evolving role of tissue factor and its pathway inhibitor

作者
Sagar N. Doshi,Jonathan D. Marmur
出处
期刊:Critical Care Medicine [Lippincott Williams & Wilkins]
卷期号:30 (Supplement): S241-S250 被引量:49
标识
DOI:10.1097/00003246-200205001-00012
摘要

OBJECTIVE: To review the experimental and clinical evidence of the emerging role of tissue factor in intravascular thrombosis and to examine evidence supporting the potential use of tissue factor pathway inhibitor as an antithrombotic therapeutic agent. DATA SOURCES AND STUDY SELECTION: A PubMed search was conducted encompassing articles in the English language relating to tissue factor and tissue factor pathway inhibitor in intravascular coagulation. CONCLUSIONS: Tissue factor, a membrane-bound procoagulant glycoprotein, is the initiator of the extrinsic clotting cascade, which is the predominant coagulation pathway in vivo. The traditional view localizes tissue factor to extravascular sites, where it remains sequestered from circulating factor VII until vascular integrity is disrupted or until tissue factor expression is induced in endothelial cells or monocytes. This perspective has been challenged since the discovery of tissue factor antigen in plasma, on circulating microparticles, and on leukocytes in whole blood. Recently, the apparent role of tissue factor has expanded with the demonstration that this molecule also functions as a signaling receptor. Recombinant tissue factor pathway inhibitor, an analogue of the physiologic inhibitor of tissue factor, is a potent inhibitor of thrombus formation in experimental models. In summary, the tissue factor pathway initiates thrombosis in vivo. In addition to its classic tissue-bound distribution, recently discovered blood-borne tissue factor may have an important procoagulant function. Despite showing promise in early human studies, a recently completed phase 3 trial of recombinant tissue factor pathway inhibitor in severe sepsis failed to show a reduction in the primary end point of 28-day all-cause mortality. Tissue factor pathway inhibitor, however, remains a plausible therapeutic agent in other conditions of increased thrombogenicity, such as acute coronary syndromes, and further studies to examine this potential are warranted.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
美好秋白完成签到,获得积分10
3秒前
5秒前
8秒前
雪山冰川发布了新的文献求助10
12秒前
开心的依柔完成签到,获得积分20
12秒前
13秒前
14秒前
浦肯野发布了新的文献求助10
18秒前
18秒前
20秒前
Ciyuan发布了新的文献求助10
21秒前
johnsonj应助科研通管家采纳,获得10
24秒前
johnsonj应助科研通管家采纳,获得30
24秒前
Criminology34应助科研通管家采纳,获得10
24秒前
Criminology34应助科研通管家采纳,获得10
24秒前
科研通AI6.4应助机智白竹采纳,获得10
33秒前
Ciyuan完成签到,获得积分10
35秒前
幸福的沛萍完成签到,获得积分10
36秒前
顺心安雁完成签到,获得积分10
36秒前
真实的曼柔完成签到 ,获得积分10
1分钟前
悲凉的雁芙完成签到,获得积分10
1分钟前
Cosmosurfer完成签到,获得积分0
1分钟前
JEREMIAH完成签到,获得积分10
1分钟前
ROMANTIC完成签到 ,获得积分0
1分钟前
淡然的代灵完成签到,获得积分10
1分钟前
飞哥与小佛完成签到,获得积分10
1分钟前
1分钟前
复杂惜珊完成签到,获得积分10
2分钟前
2分钟前
FashionBoy应助雪山冰川采纳,获得10
2分钟前
曾经凌萱发布了新的文献求助10
2分钟前
2分钟前
2分钟前
机智白竹发布了新的文献求助10
2分钟前
彭于晏应助曾经凌萱采纳,获得10
2分钟前
Criminology34应助科研通管家采纳,获得10
2分钟前
Criminology34应助科研通管家采纳,获得10
2分钟前
MchemG应助科研通管家采纳,获得10
2分钟前
Criminology34应助科研通管家采纳,获得10
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Rosenblum, Global Change Biology 800
自動車の空力技術 800
Essentials of Carbohydrate Chemistry and Biochemistry, 4th Edition 800
Organizational Behavior 510
Management and the Arts 510
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 化学工程 工程类 有机化学 物理 复合材料 生物化学 内科学 细胞生物学 基因 遗传学 免疫学 冶金 光电子学 癌症研究
热门帖子
关注 科研通微信公众号,转发送积分 7778171
求助须知:如何正确求助?哪些是违规求助? 9318750
关于积分的说明 20365670
捐赠科研通 7365258
什么是DOI,文献DOI怎么找? 3319174
关于科研通互助平台的介绍 2466923
邀请新用户注册赠送积分活动 2334499